A
Ascletis
Specialty therapeutics company developing therapeutics for the treatment of cancer and infectious diseases
About Ascletis
Ascletis Pharma Inc. is a fully integrated antiviral platform focused on developing and commercializing innovative, best-in-class drugs against Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Hepatitis B Virus (HBV). The company operates in the biopharmaceutical sector, serving both domestic and global markets. Ascletis targets healthcare providers and patients in need of advanced antiviral treatments. The business model revolves around the entire value chain from drug discovery and development to manufacturing and commercialization. Revenue is generated through the sale of its antiviral drugs, which offer high cure rates and shorter treatment periods.
The company boasts a management team with deep expertise and a proven track record, and it emphasizes a positive work environment that encourages courageous innovation. Ascletis is also committed to eliminating viral hepatitis as a major public health threat by 2030.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2011
- Headquarters
- Hong Kong
- Listing
- IPO 2018
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 45.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 2 companies, latest Aug 2019
- Capital deployed
- $25M
- Preferred round
- SERIES E
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Feb 2026 | $107M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Aug 2025 | $60M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $279K | 0% | −$51M | -18195.6% |
| 2025 | $279K | +58.1% | −$51M | -18195.6% |
| 2024 | $176K | -97.7% | −$37M | -21193% |
| 2023 | $7.8M | +4.6% | −$27M | -344.7% |
| 2022 | $7.4M | -29.6% | −$32M | -430.1% |
| 2021 | $11M | +119.6% | −$23M | -216.4% |
| 2020 | $4.8M | — | −$18M | -369.3% |
Growth signals
Latest recorded traffic for Ascletis is 6.5K monthly website visits, up 140.7% over the last three months. Ascletis's team grew 184.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
CBC Group
Tasly Pharmaceutical Group
Pavillion Capital- CCC-Bridge Capital
Goldman Sachs
Focus Media
Cambridge Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ascletis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ascletis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.